Form 8-K - Current report:
SEC Accession No. 0001437749-24-018029
Filing Date
2024-05-22
Accepted
2024-05-22 16:58:05
Documents
15
Period of Report
2024-05-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20240521_8k.htm   iXBRL 8-K 39404
2 EXHIBIT 10.1 ex_678411.htm EX-10.1 8219
  Complete submission text file 0001437749-24-018029.txt   199518

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sava-20240520.xsd EX-101.SCH 3899
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20240520_def.xml EX-101.DEF 13455
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20240520_lab.xml EX-101.LAB 17694
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20240520_pre.xml EX-101.PRE 13432
18 EXTRACTED XBRL INSTANCE DOCUMENT sava20240521_8k_htm.xml XML 4838
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 24974154
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)